Residual Cancer
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) (NCT04434040) | Dana-Farber Cancer Institute | 2020-07-02 |
Track Residual Cancer automatically
Every clearance here is in the API, with alerts when new ones post.